Loading data for CCCC — first visit, this takes a few seconds.

Alerta

C4 Therapeutics Inc. (CCCC)

NasdaqGS: CCCC · Precio en tiempo real · USD

4.18

-0.08 (-1.88%)

Al cierre: Aug 18, 2026, 8:00 PM

4.15

-0.72%

Premercado: 8:14 AM

-1.88% (1D)

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	514.25M
Ingresos (TTM)	35.04M
Beneficio neto (TTM)	-101.42M
Beta	2.95
EPS (TTM)	-0.91
Ratio PER (TTM)	n/a
Adelante PE	-4.19
P/B (TTM)	2.08
P/S (TTM)	14.68
Earnings Date	Nov 5, 2026

Precio de venta	n/a
Volumen	2,878,400
Volumen medio (20D)	3,062,358
Abierto	4.21
Anterior Cerrar	4.26
Rango del día	4.11 - 4.30
Rango de 52 semanas	1.69 - 5.17
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de CCCC

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, ...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Oct 2, 2020

Empleados 104

Bolsa de Valores NasdaqGS

Símbolo bursátil CCCC

Sitio web https://www.c4therapeutics.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de C4 Therapeutics fueron 35.95M, un aumento de 1.02% en comparación con 35.58M del año anterior. Las ganancias fueron -104.99M, una disminución de -0.31%.

Estados financieros

Sorpresa de resultados

C4 Therapeutics ha publicado sus resultados trimestrales en Aug 11, 2026:

Ingresos de $6.15M falla las estimaciones por $0, con -15.00% Disminución interanual.

EPS de -0.18 supera las estimaciones en 0.05, con 51.35% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que C4 Therapeutics Inc. publique sus resultados el Nov 5, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · Zacks

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 mes hace · Zacks

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.

1 mes hace · Zacks

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know

Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 mes hace · Insider Monkey

C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?

C4 Therapeutics, Inc. (NASDAQ:CCCC) has gained roughly 16% over the past month, mainly driven by positive phase 1 clinical trial data for Cemsidomide. The data was presented on June 11, following whic...

2 meses hace · Zacks

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.

Página 1 de 2

C4 Therapeutics Inc. (CCCC)